All In Biotech

Drug Trial Radar · NCT05484193

GnRH Agonist for Luteal Phase Support.

Comparison of Pregnancy Rates After Luteal Phase Support With GnRH Agonist Versus Progesterone - a Prospective Randomized Study

Last checked: Nov 20, 2026Latest source record: Aug 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

150

Actual

Start

Jun 8, 2020

Primary completion

Apr 15, 2022

Study completion Jan 1, 2023

Sponsor

Lead sponsor
Shaare Zedek Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Objective To assess the the efficacy of luteal support with GnRH agonist in patients undergoing IVF in antagonist-based hcg triggered cycles compared with standard luteal support with progesterone. Design prospective randomized controled study Subjects Patients who underwent antagonist-based cycles performed in the "Shaare Zedek Medical Center" IVF clinic between 2020 and 2022 Intervention Intranasal GnRH-agonist or vaginal Progesterone for luteal support. Main outcome measures Pregnancy and clinical pregnancy rates, ohss. The study cohort included 150 patients who underwent 164 cycles. A total of 127 cycles were included. Of them, 64 were treated with GnRH-a and 63 with progesterone. Hypothesis: This RCT suggests that GnRH-a for luteal phase support is associated with a higher positive β-hCG pregnancy rate and clinical pregnancy rate, compared with standard progesterone support in an antagonist-based protocol triggered with hCG, while maintaining a similar safety profile.

Conditions

  • Use of GnRH Agonist Alone for Luteal Phase Support in Fresh IVF Cycles

Interventions

  • GnRH agonistDrug

    GnRH agonist alone for luteal phase support in fresh IVF embryo transfer cycles

  • ProgesteroneDrug

    vaginal progesterone for luteal phase support

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. pregnancyTime frame: 2 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shaare Zedek medical Center

    Jerusalem, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.